RU-486 Action Date Is Sept. 30; Allen Named Reproductive Division Director
Executive Summary
The Population Council anticipates FDA action on its pending mifepristone NDA by Sept. 30.
You may also be interested in...
Female Sexual Dysfunction And Andropause Could Be Advisory Cmte. Topics
A focus of FDA's Reproductive & Urologic Drug Products Division under Acting Director Daniel Shames, MD, could be female sexual dysfunction and andropause
Female Sexual Dysfunction And Andropause Could Be Advisory Cmte. Topics
A focus of FDA's Reproductive & Urologic Drug Products Division under Acting Director Daniel Shames, MD, could be female sexual dysfunction and andropause
Searle Cytotec Pregnancy Reminder Issued As RU-486 Action Nears
Searle issued a reminder Aug. 23 that its gastric ulcer treatment Cytotec (misoprostol) is contraindicated for use in pregnant women, about a month before FDA action is expected on the pending NDA for mifepristone.